drugset / Trial / NCT03364049
Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purposes of this study are to determine the safety and tolerability of MK-7162 when administered in combination with pembrolizumab (MK-3475) and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-7162 when administered in combination with pembrolizumab.
Timeline
- Start
- 2017-12-06
- Primary completion
- 2020-10-19
- Completion
- 2020-10-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-7162 | Unknown | 25 mg | Oral |
| Subject | MK-7162 | Unknown | 50 mg | Oral |
| Subject | MK-7162 | Unknown | 100 mg | Oral |
| Subject | MK-7162 | Unknown | 200 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |